Member Info for jint

Sukura7

So now you’re a Patent enforcement expert along with being an INF specialist.

Whilst I realise there are always risks a granted patent can be subject to infringement, the penalties for infringement if upheld are extremely costly to the infringer a route unlikely to be taken lightly.

Besides SNG001, once authorised will be subject to an ‘Exclusivity’ application which will afford considerable additional protection against infringement.

It would be an extreme foolhardy act for a Pharma company to try and pit themselves against that scenario.

In essence I don’t agree with your expressed opinion on the worth and validity of the SNG001 granted patent bearing in mind the scenario I have outlined above. I suggest you are only here to sow discord to the unwary.

With that in mind why have you suggested you have invested @15p if the IP in your view has little to no relevance or value?

Sukura7

“ PS the people who keep saying there are patents: there are only formulation patents not patents to IFN. IFN per se is not patented. The patents for recombinant IFN were owned by Biogen and have expired”

No one has suggested Synairgen have IP for recombinant INF, why do you continually denigrate with the term “ONLY” the SNG001 formulation (patent granted), which enables successful administration via mesh nebulisation directly to the respiratory system along with lower dose and minimal side-effects advantage over systemic INF.

Granted patent status as you should know, is not granted without due diligence being applied by the appropriate Patent Authorities in each applicable territory.

Your continued sniping at SNG’s IP is unbecoming for someone who’s supposedly worked in the field of INF, and disrespectful of the scientists who created the formula over a number of years prior to the patent application.

Doc.D

Sukura7 stating that Synairgen had no patent for INF (which it hasn’t) and conveniently not mentioning the SNG001 formula that allows for nebulisation (patent granted), do you remember that series of posts?

Little wonder there’s a hostile response to their posts and motives.

Hi bobfraeberks,

Yes see you there (AGM).

MrCosts

They’ve already laid out their clear plan and vision with the announced Phase2 trials, we are just awaiting the get go.

MrCosts

You have a very down beat view on the Company’s prospects for the future development of SNG001.

I personally take a different view on potential timeframes with SNG’s planned Phase2 trials and patient stratification that favours SNG001.

Yes there’s still much to be accomplished however, with successful Phase2 trials and interest via J/V or other, the process (Phase3) to authorisation time wise could be expedited sooner than the ‘at least 3-4 years’ that you are suggesting.

Lastly, of course the company are eager to accomplish authorisation, why wouldn’t they be?

In the world of therapeutic development, timings don’t always run to perceived schedules. Planning trials is complexed, involving and relying on many governmental agencies outside their control, it will take time and patience.

Pjmcgra

The granted ILI patient will have a value, however this will pale into insignificance when compared to the value once SNG001 obtains authorisation.

Remember although the ILI granted patent has only approximately 6years left to run, once authorised there are two ways to extend this by means of application. These being via a SPC (Supplementary Protection Certificate) or Exclusivity.

1) SPC (Supplementary Protection Certificate) up to 5yrs + an extra 6 months for Paediatric use.

This requires SNG001 to be authorised before an application can be made.

2) The preferable one, ‘Exclusivity’, this again requires SNG001 to be authorised prior to an application being made.

Exclusivity can give additional protection for instance in the U.S. up to 12yrs, EU about to change from approximately 8years to 11years 6months.

Plus ‘’Exclusivity’’ affords greater protection (governmental) regarding possible future infringement.

In both cases the extensions are to compensate the patent owner/developer for the time taken in obtaining authorisation, (trials etc.)

However, the additional years if applied can never extend the original patent beyond its original lifespan which is 20years.

As an example, for ‘Exclusivity’ in the U.S. (up to 12yrs) if a drug is authorised with say 12yrs left on its patent life, exclusivity would only extend it back to 20years and NOT 12yrs plus 12yrs = 24yrs.

All in all, the SNG001 ILI granted patent has a healthy future once authorised plus with the potential patent extensions

will make SNG001 very attractive to BP if they’re not already.

Lastly, SNG have 2 patent applications in the pipeline for SNG001 these being: Covid and COPD/corticosteroid use.

They’ve been running the application/examination process for coming up to 4years now.

If all goes well with the applications and the eventual authorisation of SNG001 the future is bright imo.

Bobfraeberks

Looking forward to meeting up again.

Professional

Do you really have a grasp of IP value, you certainly didn’t give that impression when agreeing with Sukura7 regarding SNG’s IP.

As usual, you were playing mind games then and continue to do so with the unwary.

“And let me be clear ( as this is obviously to difficult for you to work out yourself). I do this with a very good grasp of ip value and if i invest this amount you and all others will be fully diluted so lets hope for you that if money is needed it will be via JV or equity raise for everybody. Cheers”

RE: A Plan? A product? SNG00128 Jan 2024 16:22

Sakura it is clear your knowledge is superieur to the wannabees...

Yes indeed TommyD_19, an in-kind collaboration would benefit the Casanova assay licensed manufacturer too.

Doc.D

Whilst we have no official knowledge of the nature of the relationship with the Casanovalabs regarding Universal or SGN’s P2, (apart from the AGM), I would suggest an in-kind collaboration would benefit all parties involved at this stage of their commercial development including Casanovalabs.

Spacman

“Equally, much as Synairgen may be dependent on Casanovalabs, the latter doesn't make any money unless Synairgen succeeds. So all very "symbiotic"...

Apart from the obvious advantages for SNG001, the Casanova assay test has scope for usefulness in a number applications, especially vaccine susceptibility.

“The present invention provides methods, assays and kits for assessment of patients positive for SARS-CoV-2 infection and methods of diagnosis and treatment of COVID-19 disease and for assessment and evaluation of individuals prior to vaccination with live attenuated virus vaccines, particularly including yellow fever vaccines and

COVID-19 vaccines, to assess risk for vaccine- associated disease and adverse events, and for evaluation, treatment and management of patients who develop vaccine-associated disease”

Doc.Daneeka,

None of the information from my past posts or present came from a post AGM pub chat.

The information in my notes are a reflection of the AGM or from members of the BoD post AGM chat.

The impression I took from the line “US gov conversations are positive. U.K. government more frustrating.” was in reference to the NIH and MHRA.

Although it’s apparent these trials are breaking new ground on many fronts, personally I remain confident Synairgen will meet their timeframe of H1 for starting the trials.

Yes Brand that was mentioned too, known patients that turn up frequently with respiratory viral infections.

Fruitsnveg

Rechecked my notes from AGM:

P2 trials will likely be U.K. and US trials.

US gov conversations are positive. U.K. government more frustrating.

Fruitszveg

They did indicate at the AGM, the trials will take place in the U.K as well as the U.S.

Doc.Daneeka,

They stated at the AGM, the trials will start simultaneously, with differing timeframes for finishing.

Spacman,

Fair enough, fortunately many of us take a different view.

Spacman

Interested to know why you think it is preferable to push for a sale of the company for circa 200million as opposed to waiting for the outcome of a funding transaction running in parallel, as you suggest.

Ignoring for the moment, secured before the auditors sign off tag?

Professional

My opinion, I think your assumptions are wrong on both counts.

“To be clear : them offering to buy the conpany for the cheap ( say 20p) would still be a good possibility and i think majority will accept. 100% certain i would. Cheers”